Histoplasmosis
diseaseOn this page
Also known as darling diseaseHistoplasma caused disease or disorderHistoplasma disease or disorderHistoplasma infectious disease
Summary
Histoplasmosis (MONDO:0018312) is a disease and 16 clinical trials. Top therapeutic interventions include itraconazole, amphotericin b, and fluconazole. A subtype of primary systemic mycosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 16
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | histoplasmosis |
| Mondo ID | MONDO:0018312 |
| EFO | EFO:0007310 |
| MeSH | D006660 |
| Orphanet | 390 |
| DOID | DOID:1731 |
| ICD-10-CM | B39 |
| ICD-11 | 1303003466, 1553838370 |
| NCIT | C77201 |
| SNOMED CT | 12962009 |
| UMLS | C0019655 |
| MedGen | 42468 |
| GARD | 0018692 |
| MedDRA | 10020141, 10021808 |
| Is cancer (heuristic) | no |
Also known as: darling disease · Histoplasma caused disease or disorder · Histoplasma disease or disorder · Histoplasma infectious disease
Disease family
An umbrella term covering 2 Mondo subtypes.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › systemic mycosis › primary systemic mycosis › histoplasmosis
Related subtypes (5): adiaspiromycosis, allescheriosis, blastomycosis, coccidioidomycosis, paracoccidioidomycosis
Subtypes (2): Histoplasma pericarditis, Histoplasma capsulatum infectious disease
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
1 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Amphotericin B | Approved (phase 4) |
| Ibrexafungerp | Phase 3 (in late-stage trials) |
| Itraconazole | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Fluconazole, Ranibizumab, Verteporfin.
Clinical trials & evidence
Clinical trials
Clinical trials: 16.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 6 |
| Not specified | 4 |
| PHASE2 | 3 |
| PHASE1 | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07261150 | PHASE3 | NOT_YET_RECRUITING | Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT) |
| NCT00000150 | PHASE3 | COMPLETED | Submacular Surgery Trials (SST) |
| NCT00000158 | PHASE3 | UNKNOWN | Macular Photocoagulation Study (MPS) |
| NCT00002159 | PHASE3 | COMPLETED | A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis |
| NCT00784368 | PHASE3 | COMPLETED | A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection |
| NCT03059992 | PHASE3 | COMPLETED | Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment |
| NCT00000975 | PHASE2 | COMPLETED | A Study of Itraconazole in the Treatment and Prevention of Histoplasmosis, a Fungal Infection, in Patients With AIDS |
| NCT00004808 | PHASE2 | COMPLETED | Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis |
| NCT00004811 | PHASE1/PHASE2 | COMPLETED | Phase I/II Study of Itraconazole for Blastomycosis, Histoplasmosis, and Sporotrichosis |
| NCT04059770 | PHASE2 | COMPLETED | Randomized Trial of Liposomal Amphotericin B for Histoplasmosis in AIDS Patients |
| NCT00000992 | PHASE1 | COMPLETED | A Study of Itraconazole in Preventing the Return of Histoplasmosis, a Fungal Infection, in Patients With AIDS |
| NCT02493738 | PHASE1 | COMPLETED | A Clinical Study to Evaluate the Pharmacokinetics of Lozanoc and Sporanox in Korean Healthy Male Volunteers |
| NCT00000627 | Not specified | COMPLETED | Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome |
| NCT00002438 | Not specified | COMPLETED | A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients |
| NCT00006316 | Not specified | COMPLETED | Withdrawal of Antifungal Treatment for Histoplasmosis in Patients After Improved Immune Response to Anti-HIV Drugs |
| NCT02911740 | Not specified | WITHDRAWN | Additive Benefit of the Urine LAM Test to Current TB Diagnostics in HIV Positive Adults in Panama City, Panama |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ITRACONAZOLE | 4 | 5 |
| AMPHOTERICIN B | 4 | 1 |
| FLUCONAZOLE | 4 | 1 |
| IBREXAFUNGERP | 4 | 1 |
| POSACONAZOLE | 4 | 1 |
| CHEMBL4764856 | 0 | 1 |
| HYOSCYAMINE | -1 | 5 |